: 348 – 359 . 8. Ullmann AJ Lipton JH Vesole DH . Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease . N Engl J Med 2007 ; 356 : 335 – 347 . 9. Maertens J Deeren D Dierickx D Theunissen K . Pre-emptive
Johan Maertens, Kristel Buvé and Elias Anaissie
Antonio V. Gonzalez, Andrew J. Ullmann, Nikolaos G. Almyroudis and Brahm H. Segal
J Med 2007 ; 356 : 409 – 411 . 57. Maertens J Theunissen K Verhoef G . Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective
Michael Angarone and Michael G. Ison
cytomegalovirus disease: risk factors and outcome . Blood 1997 ; 90 : 2502 – 2508 . 53. Ayala E Greene J Sandin R . Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation
Lindsey Robert Baden, William Bensinger, Michael Angarone, Corey Casper, Erik R. Dubberke, Alison G. Freifeld, Ramiro Garzon, John N. Greene, John P. Greer, James I. Ito, Judith E. Karp, Daniel R. Kaul, Earl King, Emily Mackler, Kieren A. Marr, Jose G. Montoya, Ashley Morris-Engemann, Peter G. Pappas, Ken Rolston, Brahm Segal, Susan K. Seo, Sankar Swaminathan, Maoko Naganuma and Dorothy A. Shead
preemptive therapy. This discussion addresses risk factors for infections in patients with cancer and strategies for infection prevention. Host Factors That Predispose Patients to Infectious Complications Immunodeficiencies Associated With Primary
Lindsey Robert Baden, Sankar Swaminathan, Michael Angarone, Gayle Blouin, Bernard C. Camins, Corey Casper, Brenda Cooper, Erik R. Dubberke, Ashley Morris Engemann, Alison G. Freifeld, John N. Greene, James I. Ito, Daniel R. Kaul, Mark E. Lustberg, Jose G. Montoya, Ken Rolston, Gowri Satyanarayana, Brahm Segal, Susan K. Seo, Shmuel Shoham, Randy Taplitz, Jeffrey Topal, John W. Wilson, Karin G. Hoffmann and Courtney Smith
otherwise indicated. Prevention of Infectious Diseases Preventive measures against infections in patients with cancer include upfront prophylaxis or preemptive therapy using broad spectrum antimicrobial agents directed against the most common
Barbara Burtness
was somewhat effective in reducing the number of facial lesions, but the investigators did not recommend tazarotene, as it caused significant skin irritation. 3 The STEPP trial compared preemptive and reactive skin treatment on panitumumab
Daniel L. Hertz and Vaibhav Sahai
types do not include such a statement. 2 – 8 The increased risk of life-threatening toxicity for variant carriers, so-called clinical validity, is necessary but not sufficient for recommending preemptive DPYD genetic testing. The recommendation to test
Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im and Jung-Hwan Yoon
with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy . Br J Cancer 2004 ; 90 : 1306 – 1311 . 34 Jang JW Choi JY Bae SH . A randomized controlled study of preemptive lamivudine in patients
Matthew D. Galsky, Harry W. Herr and Dean F. Bajorin
bladder cancer: G.U.O.N.E. multicenter phase III trial (Abstr #567) . Eur Urol 1998 ; 33 : 142 . 13 Wallace DM Raghavan D Kelly KA . Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder . Br
S. Machele Donat
-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder . Br J Urol 1991 ; 67 : 608 – 615 . 33 Martinez-Piñeiro JA Gonzalez Martin M Arocena F . Neoadjuvant cisplatin chemotherapy before radical cystectomy
